Microbiome Therapeutics Market

Regulation (EU) 2024/1938 on substances of human origin (SoHO) moves faecal microbiota into the same quality and safety rulebook as blood, tissues and cells, and the Finnish Medicines Agency notes that it entered into force on 7 August 2024 and applies from 7 August 2027, which forces every European stool bank to formalise donor screening before it can scale. Microbiome therapeutics are prescription medicines made of live gut bacteria, either purified from screened donor stool or grown as defined strains; the market covers approved products, regulated faecal microbiota transplantation (FMT) preparations and paid early-access supply. Douglas Insights estimates the 2025 market at USD 121.2 million, built from 20,712 treatment courses at an average realised price of USD 5,850 per course (20,712 x USD 5,850 = USD 121.2 million). The model reaches USD 499.5 million by 2035, a 15.21% revenue CAGR made of 14.3% course growth and 0.8% price growth a year. The study belongs to our pharmaceuticals research, and every input follows the Douglas Insights research methodology.

Which companies sell microbiome therapeutics today, and who wins the recurrent C. difficile prescriptions?

Nestlé Health Science leads microbiome therapeutics with an estimated 61.7% share of 2025 revenue through Vowst, the oral spore capsule, while the top three sellers hold 80.2% of value. Douglas Insights bases those shares on disclosed Rebyota sales, MaaT Pharma revenue and our course model for the United States.

Vowst is the only oral product in the category. The US Food and Drug Administration (FDA) approved it on 26 April 2023 for adults after antibiotic treatment of recurrent Clostridioides difficile infection (CDI), dosed as four capsules a day for three days. In the pivotal study, recurrence through 8 weeks was 12.4% with Vowst against 39.8% with placebo, across 89 and 93 participants. Seres Therapeutics developed the product and sold it to Nestlé in 2024; Seres now spends on SER-155, a live biotherapeutic that cut bacterial bloodstream infections by a relative 77% against placebo in a Phase 1b cohort of stem cell transplant patients. Douglas Insights puts 2025 Vowst revenue at USD 74.8 million from about 4,950 courses.

Rebyota, the rectal donor-derived suspension made by Ferring Pharmaceuticals, generated approximately USD 16.9 million of US net sales in 2025 across about 600 active accounts. RedHill Biopharma took an exclusive global licence to Rebyota on 1 September 2026 for a USD 12 million upfront payment plus tiered royalties, while Ferring keeps the plants and supplies the product. That price tag says a great deal: a donor-derived microbiome therapeutic with FDA approval changed hands for less than one year of its sales.

BiomeBank holds the Australian Register of Therapeutic Goods (ARTG) entry 399066 for Biomictra, a donor-derived product for recurrent CDI. MaaT Pharma licensed commercial rights for MaaT013 to Clinigen, which is why its first-half 2026 revenue fell to EUR 1.1 million from EUR 2.4 million. Concentration is extreme: two donor-derived brands carry 76.1% of microbiome therapeutics value.

Which product format leads microbiome therapeutics revenue: spore capsules, enemas or stool-bank FMT?

Oral purified-spore capsules lead microbiome therapeutics with 61.7% of 2025 revenue, USD 74.8 million, because one product sells at the highest realised price to the largest insured patient pool. Stool-bank FMT preparations supply most courses but little value, and defined consortia grow fastest from a small base.

Oral purified-spore capsules are worth USD 74.8 million and reach USD 289.6 million in 2035 at 14.5% a year; a 12-capsule course taken at home removes the colonoscopy or enema visit, and that convenience is why prescribers pay roughly USD 15,100 per realised course. Rectal donor-derived suspensions hold 18.3% and USD 22.2 million, growing only 8.9% because a single-dose enema needs a clinic visit and its US owner changed in 2026. Stool-bank FMT preparations account for 15.6% and USD 18.9 million: about 13,040 courses at around USD 1,450 each, which makes them 63% of all courses but a small share of money. Their 10.8% growth comes from hospitals in Europe that must buy screened material once the SoHO rules apply.

Defined-consortium and early-access live biotherapeutics are the fastest-growing format at 34.8% a year, from USD 5.3 million to USD 105.6 million. The reason is manufacturing: strains grown from clonal cell banks avoid donor screening entirely, and VE303 reports Phase 3 data in the first half of 2027. Our 2025 base counts only about 172 paid courses, mostly MaaT013 early access in France.

The model also splits microbiome therapeutics by indication: recurrent C. difficile infection carries about 99% of 2025 courses, acute graft-versus-host disease most of the remainder, and other indications such as bloodstream infection prevention stay in trials. By care setting, demand runs through the hospital outpatient clinic, the gastroenterology office and the transplant centre.

Why are recurrent C. difficile infections the main demand engine for microbiome therapeutics?

Recurrent C. difficile infection supplies about 99% of microbiome therapeutics courses and drives the 14.3% yearly course growth. Up to 165,000 US cases a year recur, yet fewer than 21,000 courses were treated worldwide in 2025. Four drivers add 5.6, 3.9, 2.7 and 2.1 points of volume growth.

The untreated recurrence pool

The pool is large and barely touched. CDI causes an estimated 3.6 million cases a year worldwide and about half a million in the United States, according to the RedHill licence announcement, and up to approximately 165,000 US cases lead to one or more recurrences. The FDA counts 15,000 to 30,000 US deaths a year linked to CDI. Against that, Douglas Insights counts only 7,500 approved-product courses in 2025, under 5% of the US recurrent pool. Moving prescribers from repeat antibiotic cycles to a microbiome therapeutic after the second episode adds 5.6 points a year to course growth.

Oral dosing moves treatment out of the endoscopy suite

Vowst replaced a procedure with a prescription. Four capsules a day for three days, approved by the FDA on 26 April 2023, can be dispensed by a specialty pharmacy, which lets community gastroenterologists and infectious disease physicians treat patients who never reach a colonoscopy slot. Capsule courses grow 14.5% a year in our model, and the shift from procedure to pharmacy contributes 3.9 points of microbiome therapeutics volume growth.

New indications in transplant and oncology

Indications beyond CDI add 2.7 points. MaaT013 targets acute graft-versus-host disease (aGvHD) with gastrointestinal involvement, and its French early-access programme earned EUR 4.4 million in 2025, up 38% on 2024. SER-155 targets bloodstream infections after allogeneic haematopoietic stem cell transplant (allo-HSCT), and the US Biomedical Advanced Research and Development Authority (BARDA) co-funds VE303. Each transplant course carries a price above USD 30,000 in our model, so a few hundred patients move revenue more than thousands of stool-bank courses.

Regulated stool banks outside the United States

The final 2.1 points come from regulated supply outside North America. Once Regulation (EU) 2024/1938 applies on 7 August 2027, European hospitals that prepared FMT in-house will either register as SoHO entities or buy screened preparations, and the Finnish Medicines Agency confirms faecal microbiota sits inside the new scope. Australia already lists a registered product. Douglas Insights expects European microbiome therapeutics revenue to rise from USD 18.1 million to USD 81.2 million by 2035 on that formalisation.

Which hurdles slow microbiome therapeutics after the Xervyteg rejection in Europe?

Three hurdles take about 4.6 points off gross microbiome therapeutics course growth, leaving the net 14.3% leg: weak commercial economics for donor-derived brands, regulatory rejection in Europe and cheap compounded FMT. Without them, courses would grow near 18.9% a year to 2035.

Commercial economics come first and remove 2.1 points. Ferring decided in 2025 that it lacked commercial critical mass in the therapy area, and RedHill paid only USD 12 million upfront for global Rebyota rights in September 2026 against USD 16.9 million of 2025 US sales. A brand that cannot fund its own field force grows slowly, and the rectal format grows only 8.9% a year in our model.

Regulatory risk removes 1.5 points. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a negative trend vote for MaaT013 on 20 May 2026 and kept a negative opinion after re-examination in September 2026, according to MaaT Pharma. The company now runs a strategic review with cash of EUR 17.1 million at 30 June 2026 and a runway to December 2026. No donor-derived microbiome therapeutic holds an EU marketing authorisation, so Europe stays an early-access and stool-bank market until at least 2028.

Compounded and hospital-prepared FMT removes the last 1.0 point. A stool-bank course priced near USD 1,450 competes with branded courses priced six to ten times higher, and payers notice. Microbiome therapeutics companies also face trial costs: the VE303 Phase 3 needs more than 150 sites to enrol, which keeps defined-consortium launches behind 2027.

Where are microbiome therapeutics bought, and which region grows fastest?

North America buys 73.7% of microbiome therapeutics, USD 89.3 million in 2025, because both FDA-approved products sell there. Asia Pacific grows fastest at 17.9% a year as an Australian registration widens hospital access from a low base, while Europe follows at 16.2%.

North America reaches USD 352.0 million by 2035 at 14.7%, slower than the global rate because the base is already commercial. Europe holds 14.9% today, USD 18.1 million, mostly stool-bank preparations and French early access, and climbs to USD 81.2 million. Asia Pacific grows from USD 8.0 million to USD 41.5 million at 17.9%, the fastest rate, because Biomictra gives Australia a registered donor-derived product and regional hospitals start from a low treated share. Latin America accounts for USD 3.1 million, 2.6% of microbiome therapeutics value, rising at 15.6%. The Middle East and Africa holds USD 2.7 million and reaches USD 11.6 million. The wildcard is the Middle East: Gulf transplant centres buying aGvHD therapies could add more than our 15.69% rate implies.

How much does a course of microbiome therapeutics cost per patient?

Realised microbiome therapeutics prices run from about USD 1,450 for a stool-bank FMT course to USD 31,000 for an early-access transplant course, with a blended 2025 average of USD 5,850. Branded recurrent CDI products sit in the middle at USD 8,700 to USD 15,100.

The one list price we could read is Rebyota: Ferring publishes a wholesale acquisition cost (WAC) of USD 9,552.17 for a single-dose kit, accurate as of 26 June 2026. Douglas Insights calculates a net realised Rebyota price of about USD 8,600 after rebates and channel fees, which implies roughly 1,965 US courses behind the USD 16.9 million of 2025 sales. Vowst, as an oral 12-capsule course, realises about USD 15,100 in our model.

The blended price rises only 0.8% a year, to USD 6,335 in 2035. List increases on branded microbiome therapeutics are offset by mix: cheaper stool-bank courses grow in Europe, and RedHill has signalled a leaner commercial model for Rebyota.

Which rules govern donor screening for faecal microbiota and live biotherapeutics?

Two rulebooks govern microbiome therapeutics: medicine law for approved products such as Vowst and Rebyota, and Regulation (EU) 2024/1938 for donor-derived faecal microbiota from 7 August 2027. The first sets efficacy trials; the second sets donor screening, traceability and vigilance for about 15.6% of 2025 value.

In the United States the FDA regulates microbiome therapeutics as biologics, so each product needs a licence backed by controlled trials, like the 182-patient efficacy comparison behind Vowst. In Europe the SoHO regulation, which entered into force on 7 August 2024, adds faecal microbiota and human breast milk to blood, tissues and cells. Stool banks must register, screen donors to common standards and report adverse reactions. Products that become industrial medicines, such as MaaT013, still need a marketing authorisation from the European Commission on CHMP advice. Australia regulates Biomictra through the Therapeutic Goods Administration (TGA).

Which indications beyond C. difficile, such as graft-versus-host disease, come next for microbiome therapeutics?

Transplant medicine is the next microbiome therapeutics indication, and our model gives non-CDI use under 1% of 2025 courses but 4.4% of value, because aGvHD and bloodstream infection courses price above USD 30,000. Inflammatory bowel disease has proved harder, so ulcerative colitis stays outside the base case.

MaaT013 remains the most advanced aGvHD candidate. MaaT Pharma plans a registrational Phase 3, PHOENIX, of about 138 patients randomised 1:1 against best available therapy, with first enrolment targeted for the first half of 2027, subject to financing. SER-155 is heading to a Phase 2 study in allo-HSCT. Ulcerative colitis is the cautionary tale: Vedanta reported in August 2025 that VE202 missed its Phase 2 primary endpoint. Douglas Insights therefore models no inflammatory bowel disease revenue before 2030.

What does the RedHill licence of Rebyota reveal about microbiome therapeutics deal values?

The RedHill licence values a commercial microbiome therapeutic at about 0.7 times its 2025 US sales: USD 12 million upfront against USD 16.9 million of revenue, plus royalties. Donor-derived products now trade as specialty assets, not platform bets, and that sets expectations for every pending deal.

The contrast with 2024 is sharp. Seres agreed to sell Vowst to Nestlé for a USD 175 million cash infusion less about USD 20 million of settlements, and Seres reported USD 75 million of installment payments received during 2025. That valuation priced growth; the September 2026 Rebyota licence priced a slower, account-based business with about 600 hospital and clinic customers. Douglas Insights puts the rectal format at USD 52.0 million by 2035, below a quarter of the capsule format.

What if VE303 succeeds in 2027: how far does the 2035 microbiome therapeutics forecast move?

A positive VE303 readout lifts the 2035 microbiome therapeutics total to USD 812.2 million in our faster case, against USD 499.5 million in the base case and USD 323.6 million if trials and payers disappoint. Volume, not price, separates the three outcomes.

The faster case assumes VE303 reports positive Phase 3 data in the first half of 2027, as Vedanta expects after raising USD 60 million in August 2026, and that the SoHO rules from 7 August 2027 push European hospitals onto screened supply. The slower case assumes Xervyteg never reaches the EU market and Rebyota volumes stall. Sensitivity is steep: one extra point of course growth adds USD 45.5 million to the 2035 total, and one point less removes USD 42.0 million.

Our 15.21% revenue CAGR sits below published forecasts of 21.5% to 54.8% a year. The gap is deliberate. We count realised courses at observed prices, and two 2026 events, the CHMP rejection of MaaT013 and the low Rebyota licence fee, argue against the steeper curves.

Douglas Exclusive: the Microbiome Therapeutics Access Index

The Microbiome Therapeutics Access Index is a Douglas Insights model, not an official ranking, built from 14 inputs. Those are 9 sourced facts (three product approvals or registrations, one EU regulation, one CHMP opinion, two company sales disclosures, one list price and one trial footprint) plus our 5 regional revenue rows, and the index scores each region from 0 to 100.

The index weights four components: approved or registered products (35%), 2025 revenue depth against the largest region (30%), 2026 to 2035 growth (15%) and rulebook certainty for donor-derived and defined-strain products (20%). The rulebook score is our judgment, stated so readers can change it.

The finding: North America scores 87.6, well ahead of any other region, while Asia Pacific (50.8) beats Europe (37.1) despite a smaller microbiome therapeutics base, because Australia already registers a donor-derived product and Europe has none. Europe gains about 9 index points if a microbiome product wins EU approval, which is the single largest swing in the model.

How the model counts microbiome therapeutics courses: what are the receipts?

Douglas Insights counts 20,712 microbiome therapeutics courses in 2025 across 4 product formats and 5 regions, priced at a blended USD 5,850, which gives USD 121.2 million. Each format is courses multiplied by realised price, and the four formats sum to the total.

The receipts by format: 4,950 capsule courses x USD 15,100; 2,550 rectal courses x USD 8,700; 13,040 stool-bank courses x USD 1,450; and 172 early-access courses x USD 31,000. Two cross-checks anchor the build. Our Rebyota estimate of USD 17.4 million, which includes a small ex-US amount, sits 3.0% above the disclosed USD 16.9 million of US sales. MaaT early-access revenue of EUR 4.4 million converts to about USD 5.0 million, matching our transplant-course value within 7%. Course growth of 14.3% and price growth of 0.8% compound to 15.21%, and 78,829 courses at USD 6,335 give the 2035 figure. Readers comparing adjacent studies can see the Probiotic Culture Market, the Pharma Microbiology Testing Kits Market and the Cell and Gene Therapy CDMO Services Market.

Sources

1. US Food and Drug Administration FDA approves Vowst (2023)
2. Finnish Medicines Agency (Fimea) New regulation on substances of human origin (2024)
3. Ferring Pharmaceuticals Rebyota WAC pricing sheet (2026)
4. RedHill Biopharma RedHill acquisition of commercialization rights to Rebyota (2026)
5. MaaT Pharma Half-year 2026 results (2026)
6. Vedanta Biosciences Vedanta Biosciences secures USD 60 million (2026)
7. SEC EDGAR Seres Therapeutics Form 10-Q, Q3 2025 (2025)
8. BiomeBank BiomeBank Biomictra registration (2022)